RE:Raised TargetsThis is what I find to be most appealing in your post retired.. * Leede Jones Gable’s Douglas Loe to $16.25 from $15 with a “buy” rating. “We continue to be impressed by Quipt’s ability to scale operations without sacrificing EBITDA margin or operating cash flow generation, even with inflationary cost escalation and labor constraints producing operational headwinds across most healthcare services firms, and we expect that trend to continue,” said Mr. Loe. “Key macro factors that should facilitate margin stability include the scheduled increase in CPI-based Medicare funding increases of 6.4 per cent to 9.1 per cent next year, and the elimination of the requirement for respiratory patients to receive physician-endorsed certificates of medical necessity before actively seeking out home-based respiratory care, a long overdue initiative that should enhance Quipt’s annual patients served.”